Is Tirzepatide considered natty?

Tirzepatide is generally regarded as compatible with natural bodybuilding. Most sanctioning bodies do not prohibit its therapeutic use, though rules vary by federation.

Is Tirzepatide on the WADA prohibited list?

As of the current prohibited list, Tirzepatide is not explicitly banned by WADA, though regulations can change. Always verify against the current year's WADA prohibited list before competition.

How is Tirzepatide administered?

Tirzepatide is typically administered via: subcutaneous injection. Dosage and administration protocols vary; see the Dosage section for details.

Tirzepatide - Retapedia | Natty or Not?

Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Tirzepatide
Structure of Tirzepatide. 39-aa dual GIP/GLP-1 agonist with Aib at positions 2 and 13, γGlu–2×OEG–C20 diacid lipidation on Lys20, and a C-terminal amide. Source: Wikimedia Commons.
Identification
Class	Modified peptide
PubChem CID	156588324
Other names	Tirzepatide · GIP/GLP-1 dual agonist
Trade names	Mounjaro Zepbound
Administration
Routes	Subcutaneous injection
Status
Verdict	Natty
WADA	Not prohibited^[4]
Article meta
Slug	`tirzepatide`
Last edited	May 25, 2026
Tags	fat loss, weight loss, diabetes, cardiovascular, sleep apnea, subcutaneous

Tirzepatide (also known as Tirzepatide or GIP/GLP-1 dual agonist) is a therapeutically researched peptide studied for its effects on fat loss, weight loss, diabetes. FDA-approved dual GIP/GLP-1 agonist (Mounjaro/Zepbound) with superior 21% weight loss, first OSA medication, excellent diabetes control. GI side effects common.

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly as Mounjaro (type 2 diabetes, 2.5-15mg weekly) and Zepbound (obesity and obstructive sleep apnea, 2.5-15mg weekly). Unique imbalanced agonist with greater GIP receptor engagement than GLP-1, plus biased GLP-1 agonism favoring cAMP generation over β-arrestin recruitment, enhancing insulin secretion. SURMOUNT trials demonstrated exceptional weight loss: 20.9% at 72 weeks (15mg dose), with 50-57% of participants achieving ≥20% weight loss.

Natty status

Tirzepatide is generally regarded as compatible with natural bodybuilding, though competitive federations may differ. See § Natty status.

Contents [hide]

1 Overview
2 Mechanism of action
3 Reported effects
4 Dosage and administration
5 Natty status
6 Research
7 Related compounds
8 References
9 External links

Overview

SURMOUNT-4 showed 25.3% mean weight reduction long-term.

Unprecedented diabetes efficacy in SURPASS trials with HbA1c reductions of 1.9-2.6% and weight loss of 6.6-13.9kg, superior to semaglutide 1mg.

December 2024 FDA approval as first medication for moderate-to-severe obstructive sleep apnea in adults with obesity, reducing breathing disruptions by 25-29 per hour (5x more effective than placebo).

Cardiovascular meta-analysis showed HR 0.80 for MACE-4, with SURPASS-4 showing HR 0.50 at 15mg dose.

Common side effects are gastrointestinal (nausea, vomiting, diarrhea 16.24% vs 8.63% placebo), typically mild-to-moderate, transient, occurring during dose escalation. 2024 systematic review found no association with pancreatitis.

Gradual titration every 4 weeks (2.5mg steps) minimizes adverse events.

Available in 6 strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg.

Mechanism of action

Reduces appetite for 21% weight loss. Significantly improves blood sugar and diabetes. Reduces sleep apnea breathing disruptions by 50%.

Reported effects

Effects reported in the literature and from preclinical models include:

Tirzepatide reduces heart failure hospitalizations and improves symptoms and functional capacity in obese patients with heart failure with preserved or mildly reduced ejection fraction. ^[3] Phase III
In a meta-analysis of 11 RCTs comprising 13,378 participants, tirzepatide monotherapy reduced heart failure risk by 57% relative to controls in patients with T2DM or obesity. ^[1] Phase III
Tirzepatide is an effective pharmacotherapy option for weight management in patients who cannot achieve sufficient weight loss through lifestyle modification alone. ^[2] Anecdotal

Evidence grades: FDA approved Phase III Phase II Phase I Preclinical Anecdotal

Dosage and administration

⚠

Dosage information is included for encyclopedic purposes only. Retapedia does not provide medical advice. See Retapedia : Medical disclaimer.

General

Week 1-4: 2.5mg once weekly (subcutaneous, starting dose)
Week 5-8: 5.0mg once weekly
Week 9-12: 7.5mg once weekly (optional step)
Week 13-16: 10mg once weekly
Week 17-20: 12.5mg once weekly (optional step)
Week 21+: 15mg once weekly (maximum dose)
Escalate by 2.5mg every 4 weeks minimum
Do not increase faster than 2.5mg per 4 weeks

Maintenance

5mg, 10mg, or 15mg based on response/tolerability

Available strengths

2.5, 5, 7.5, 10, 12.5, 15mg per 0.5mL

Natty status

See also: Peptide § Natty status

Tirzepatide is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.^[4]